Form 8-K - Current report:
SEC Accession No. 0001193125-26-245163
Filing Date
2026-05-28
Accepted
2026-05-28 16:01:40
Documents
12
Period of Report
2026-05-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d131735d8k.htm   iXBRL 8-K 28883
2 EX-10.1 d131735dex101.htm EX-10.1 791023
  Complete submission text file 0001193125-26-245163.txt   1125088

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20260522.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20260522_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20260522_pre.xml EX-101.PRE 10814
16 EXTRACTED XBRL INSTANCE DOCUMENT d131735d8k_htm.xml XML 3727
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 261035405
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)